Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Cited by (1,030)

Items 601–700 of 1,030

1. Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
   Davide Stolfo, Lars H. Lund, Lina Benson, Felix Lindberg, Giulia Ferrannini, Ulf Dahlström, Gianfranco Sinagra, Giuseppe M.C. Rosano, Gianluigi Savarese · 2023 · European Journal of Heart Failure
2. Association Between Loop Diuretic Dose Changes and Outcomes in Chronic Heart Failure: Observations from the ESC-EORP Heart Failure Long-Term Registry
   Chris J. Kapelios, Cécile Laroche, María G. Crespo‐Leiro, Stefan D. Anker, Andrew J.S. Coats, Beatriz Díaz Molina, Gerasimos S Filippatos, Mitja Lainščak, Aldo Pietro Maggioni, Theresa A. McDonagh et al. · 2020 · European Journal of Heart Failure
3. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
   Ann Wan-Chin Ling, Cze-Ci Chan, Shao‐Wei Chen, Yi‐Wei Kao, Chien-Ying Huang, Yi‐Hsin Chan, Pao‐Hsien Chu · 2020 · Cardiovascular Diabetology
4. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
   Matthias Rau, Kirsten Thiele, Niels‐Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke · 2021 · Cardiovascular Diabetology
5. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
   Katrine Meyer Lauritsen, Bent R.R. Nielsen, Lars Poulsen Tolbod, Mogens Johannsen, Jakob Hansen, Troels Krarup Hansen, Henrik Wiggers, Niels Møller, Lars Christian Gormsen, Esben Søndergaard · 2020 · Diabetes
6. Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
   Maximilian Trum, Johannes Riechel, Stefan Wagner · 2021 · International Journal of Molecular Sciences
7. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study
   Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P. Keszei, Nikolaus Marx, Michael Lehrke · 2021 · Diabetes Obesity and Metabolism
8. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy
   Lixia Zhang, Chenchen Ai, Ming Bai, Jinglei Niu, Zheng Zhang · 2022 · International Journal of Molecular Sciences
9. Prevention of cardiorenal complications in people with type 2 diabetes and obesity
   Daniel J. Drucker · 2024 · Cell Metabolism
10. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
    Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, Marta Belmonte, Emanuel Raschi, Guido Di Dalmazi, Sara Amicone, Lisa Canton, Damiano Fedele, Nicole Suma et al. · 2025 · Pharmacology & Therapeutics
11. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
    Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2020 · International Journal of Molecular Sciences
12. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
    Kim Alexander Connelly, Yanling Zhang, Jean‐François Desjardins, Linda Nghiem, Aylin Visram, Sri Nagarjun Batchu, Veera Ganesh Yerra, Golam Kabir, Kerri Thai, Andrew Advani et al. · 2020 · Cardiovascular Diabetology
13. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
    Kazuomi Kario, Keith C. Ferdinand, James Henry O’Keefe · 2020 · Progress in Cardiovascular Diseases
14. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence
    Marco Giuseppe Del Buono, Giulia Iannaccone, Roberto Scacciavillani, Salvatore Carbone, Massimiliano Camilli, Giampaolo Niccoli, Barry A. Borlaug, Carl J. Lavie, Ross A Arena, Filippo Crea et al. · 2020 · Progress in Cardiovascular Diseases
15. Fibroblast Growth Factor 23: A Biomarker of Fibrosis and Prognosis in Heart Failure with Preserved Ejection Fraction
    Clotilde Roy, Sibille Lejeune, Alisson Slimani, Christophe de Meester, Sylvie A. Ahn, Michel F. Rousseau, Mihaela Silvia Amzulescu, Audrey Ginion, Benjamin Ferracin, Agnès Pasquet et al. · 2020 · ESC Heart Failure
16. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
    Kana N. Miyata, Chao‐Sheng Lo, Shuiling Zhao, Min-Chun Liao, Yuchao Pang, Shiao‐Ying Chang, Junzheng Peng, Matthias Kretzler, János G. Filep, Julie R. Ingelfinger et al. · 2021 · Clinical Science
17. Mechanisms and Models in Heart Failure
    Douglas L. Mann, Gary Michael Felker · 2021 · Circulation Research
18. Heart Failure Subtypes and Cardiomyopathies in Women
    Ersilia M. DeFilippis, Anna Beale, Trejeeve Martyn, Anubha Agarwal, Uri Elkayam, Carolyn S.P. Lam, Eileen Hsich · 2022 · Circulation Research
19. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
    Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece et al. · 2022 · Cardiovascular Diabetology
20. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens—From a Cardiologist’s View
    Angelos C. Mitsas, Mohamed Elzawawi, Sophie I. Mavrogeni, Michael Boekels, Asim Ali Khan, Mahmoud Eldawy, Ioannis Stamatakis, Dimitrios Kouris, Baraa Daboul, Oliver Gunkel et al. · 2022 · Journal of Clinical Medicine
21. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis
    Rami Aldafas, Thomas Simon James Crabtree, Mohammed A. Alkharaiji, Yana Vinogradova, ISKANDAR RAUF IDRIS · 2023 · Age and Ageing
22. Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison with Contemporary Clinical Trials
    John R. Teerlink, Rafael Díaz, Gary Michael Felker, John J.V. McMurray, Marco Metra, Scott David Solomon, Kirkwood F. Adams, Inder S. Anand, Alexandra Arias‐Mendoza, Tor Biering‐Sørensen et al. · 2020 · European Journal of Heart Failure
23. Metabolic Consequences of Solid Organ Transplantation
    Mamatha Bhat, Shirine E. Usmani, Amirhossein Azhie, Minna Woo · 2020 · Endocrine Reviews
24. Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes
    Kristen Sullivan, Barbara Stella Doumouras, Bernadet T. Santema, Mary Norine Walsh, Pamela S. Douglas, Adriaan A. Voors, Harriette G.C. Van Spall · 2020 · Canadian Journal of Cardiology
25. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
    Ning Li, Dan Lv, Zhu X, Ping Wei, Yuan Gui, Shijia Liu, Enchao Zhou, Min Zheng, Dong Feng Zhou, Lu Zhang · 2021 · Frontiers in Medicine
26. Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
    Cheol Ho Park, Bin Lee, Myeonggil Han, Woo Joong Rhee, Man Sup Kwak, Tae‐Hyun Yoo, Jeon‐Soo Shin · 2022 · Cell Death Discovery
27. Diabetic cardiomyopathy
    Ana Lorenzo-Almorós, J.M. Cepeda-Rodrigo, Óscar Lorenzo · 2020 · Revista Clínica Española (English Edition)
28. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
    Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha R. Ambwani, Jaykaran Charan, Shoban B. Varthya · 2022 · Journal of Family Medicine and Primary Care
29. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction
    Akshay Suvas Desai, Pardeep S. Jhund, Brian Lee Claggett, Muthiah Vaduganathan, Zi Michael Miao, Toru Kondo, Ebrahim Barkoudah, Abdel Brahimi, Eugene C. Connolly, Peter V. Finn et al. · 2022 · JAMA Cardiology
30. Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
    Ankeet S. Bhatt, Anubodh Sunny Varshney, Alea Moscone, Brian Lee Claggett, Zi Michael Miao, Safia Chatur, Mathew S. Lopes, John W. Ostrominski, Maria A. Pabón, Ozan Ünlü et al. · 2023 · Journal of the American College of Cardiology
31. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
    Patrick Barry Mark, Pantelis A. Sarafidis, Robert Ekart, Charles Joseph Ferro, Olga C. Balafa, Beatriz Fernández‐Fernández, William Guy Herrington, Patrick Rossignol, Lucia Del Vecchio, José Manuel Valdivielso et al. · 2023 · Nephrology Dialysis Transplantation
32. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study
    Salvatore Carbone, Hayley Billingsley, Justin McNair Canada, Edoardo Bressi, Brando Rotelli, Dinesh Kadariya, Dave L. Dixon, Roshanak Markley, Cory Ross Trankle, Richard H. Cooke et al. · 2020 · Diabetes/Metabolism Research and Reviews
33. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation
    Carlotta Perego, Marco Sbolli, Claudia Specchia, Mona Fiuzat, Zachary Ryan McCaw, Marco Metra, Chiara Oriecuia, Giulia Peveri, Lee‐Jen Wei, Christopher M. O’Connor et al. · 2020 · JACC Heart Failure
34. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
    Emily E. Brown, John P.H. Wilding, Uazman Alam, Thomas M. Barber, Janaka J. Karalliedde, Daniel James Cuthbertson · 2020 · Annals of Medicine
35. Thrombolysis In Myocardial Infarction (TIMI) Study Group
    Marc Steven Sabatine, Eugene Braunwald M. D · 2021 · Journal of the American College of Cardiology
36. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
    Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Melgaard Videbæk, Christian Tuxen, Julie Hempel Larsen, Camilla Fuchs Andersen, Finn Gustafsson, Lars Køber et al. · 2022 · Cardiovascular Diabetology
37. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
    Ren Jie Phang, Rebecca Helen Ritchie, Derek John Hausenloy, Jarmon G. Lees, Shiang Yong Lim · 2022 · Cardiovascular Research
38. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
    Kamil F. Faridi, Elias J. Dayoub, Joseph S. Ross, Sanket Shishir Dhruva, Tariq Ahmad, Nihar R. Desai · 2022 · Journal of the American College of Cardiology
39. Emerging molecular imaging targets and tools for myocardial fibrosis detection
    Anna Kate Barton, Evangelos Tzolos, Rong Bing, Trisha Singh, Wolfgang Weber, Markus Schwaiger, Zohreh Varasteh, Riemer H. J. A. Slart, David Ernest Newby, Marc Richard Dweck · 2022 · European Heart Journal - Cardiovascular Imaging
40. Treatment of chronic kidney disease in older populations
    Seiji Kishi, Hiroyuki Kadoya, Naoki Kashihara · 2024 · Nature Reviews Nephrology
41. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
    Abhinav Sharma, Subodh Verma · 2019 · Canadian Journal of Diabetes
42. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams, Asif Nawaz, Marc Evans · 2019 · Diabetes Therapy
43. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
    Daryl J. Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L. Cutler, Neeta B. Amin, Steven G. Terra, Rebecca A. Boyd, Rajesh Krishna, Vaishali Sahasrabudhe · 2020 · Clinical Pharmacokinetics
44. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
    Pardeep S. Jhund, Piotr P. Ponikowski, Kieran F. Docherty, Samvel B. Gasparyan, Michael Böhm, Chern‐En Chiang, Akshay Suvas Desai, Jonathan G. Howlett, Masafumi Kitakaze, Mark Colquhoun Petrie et al. · 2021 · Circulation
45. Cardiac, Renal, and Metabolic Effects of Sodium–Glucose Co-Transporter 2 Inhibitors: A Position Paper from the European Society of Cardiology Ad-Hoc Task Force on Sodium–Glucose Co-Transporter 2 Inhibitors
    William Guy Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H. Lund, Paul Dendale, Petar M Seferovic, Giuseppe M.C. Rosano, Natalie Staplin et al. · 2021 · European Journal of Heart Failure
46. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
    David Z.I. Cherney, Ele Ferrannini, Guillermo E. Umpierrez, Anne L. Peters, Julio Rosenstock, Amy K. Carroll, Pablo Lapuerta, Phillip Lee Banks, Rajiv Agarwal · 2021 · Diabetes Obesity and Metabolism
47. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
    Panagiota Nikolaou, Nikolaos Mylonas, Manousos Makridakis, Marina Makrecka‐Kuka, Aikaterini Iliou, Stelios Zerikiotis, Panagiotis Efentakis, Stavros Kampoukos, Nikolaos G Kostomitsopoulos, Reinis Vilšķe̅rsts et al. · 2022 · Basic Research in Cardiology
48. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction
    Gregory D. Lewis, Adriaan A. Voors, Alain Cohen Solal, Marco Metra, David J. Whellan, Justin Adrian Ezekowitz, Michael Böhm, John R. Teerlink, Kieran F. Docherty, Renato D. Lópes et al. · 2022 · JAMA
49. Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
    Jiahan Ke, Jianan Pan, Hao Lin, Jun Gu · 2022 · ESC Heart Failure
50. The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies
    Zhulan Cai, Cencen Wu, Yuan Xu, Jiageng Cai, Menglin Zhao, Lingyun Zu · 2022 · Aging and Disease
51. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
52. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
    Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg, Esther Moonen‐Kornips, RUSSELL L. ESTERLINE, Matthijs K. C. Hesselink, Joris Hoeks J, Vera B. Schrauwen‐Hinderling, Bas Havekes, Jan Oscarsson et al. · 2021 · Diabetes Care
53. The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
    Petra Grubić Rotkvić, Zrinka Planinić, Ana-Marija Liberati Pršo, Jozica Šikić, Edvard Galić, Luka Rotkvić · 2021 · International Journal of Molecular Sciences
54. Current and emerging drug targets in heart failure treatment
    Nicolò Ghionzoli, Francesco Gentile, Annamaria Del Franco, Vincenzo Castiglione, Alberto Aimo, Alberto Giannoni, Silvia Burchielli, Matteo Cameli, Michele Emdin, Giuseppe Vergaro · 2021 · Heart Failure Reviews
55. Ketones: the double-edged sword of SGLT2 inhibitors?
    Beatrice C. Lupsa, Richard Glenn Kibbey, Silvio E. Inzucchi · 2022 · Diabetologia
56. Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
    Wei Yu, De Xie, Tetsuya Yamamoto, Hidenori Koyama, Jidong Cheng · 2023 · Reviews in Endocrine and Metabolic Disorders
57. Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats
    Takuya Koizumi, Masaya Watanabe, Takashi Yokota, Masumi Tsuda, Haruka Handa, Jiro Koya, Kotaro Nishino, Daishiro Tatsuta, Hiroyuki Natsui, Takahide Kadosaka et al. · 2023 · Frontiers in Cardiovascular Medicine
58. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
    LAURA P. COHEN, Nicolás Isaza, Inmaculada Hernandez, Gregory D. Lewis, Jennifer E. Ho, Gregg C. Fonarow, Dhruv S. Kazi, Brandon Kyle Bellows · 2023 · JAMA Cardiology
59. Recent successes in heart failure treatment
    Carolyn S.P. Lam, Kieran F. Docherty, Jennifer E. Ho, John J.V. McMurray, Peder Langeland Myhre, Torbjørn Omland · 2023 · Nature Medicine
60. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
    Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina Tiziana Russo et al. · 2024 · Metabolites
61. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
    Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández · 2024 · Clinical Kidney Journal
62. Cardiovascular–Kidney–Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?
    Victoria Mutruc, Cristina Bologa, Victorița Șorodoc, Alexandr Ceasovschih, Bianca Codrina Morărașu, Laurențiu Șorodoc, Oana Catar, Cătălina Lionte · 2025 · Journal of Clinical Medicine
63. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
64. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
    Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini · 2021 · Cardiovascular Diabetology
65. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors – Lessons From a Case Series and Strategies to Decrease Incidence
    Mehta, Paras B., Robinson, Andrew, Burkhardt, Daniel, Rushakoff, Robert J. · 2022 · Endocrine Practice
66. Estimated plasma volume status in heart failure: clinical implications and future directions
    Masatake Kobayashi, Nicolas Girerd, Kévin Duarte, Tahar Chouihed, Taishiro Chikamori, Bertram Pitt, Faiez M. Zannad, Patrick Rossignol · 2021 · Clinical Research in Cardiology
67. Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study
    Jonas Oldgren, Sanna Laurila, Axel Åkerblom, Aino Latva‐Rasku, Eleni Rebelos, Henrik Isackson, Maria Saarenhovi, Olof Eriksson, Kerstin Heurling, Edvin Johansson et al. · 2021 · Diabetes Obesity and Metabolism
68. Chronic kidney disease in patients with diabetes mellitus
    Espen Nordheim, Trond Geir Jenssen · 2021 · Endocrine Connections
69. Translation of New and Emerging Therapies for Genetic Cardiomyopathies
    Adam S. Helms, Andrea D. Thompson, Sharlene M. Day · 2021 · JACC Basic to Translational Science
70. Sex-Based Differences in Heart Failure
    Sadiya S. Khan, Lauren Brittany Beach, Clyde W. Yancy · 2022 · Journal of the American College of Cardiology
71. Vericiguat and NT-proBNP in Patients with Heart Failure with Reduced Ejection Fraction: Analyses from the VICTORIA Trial
    Michele Senni, José López-Sendón, Alain Cohen Solal, Piotr P. Ponikowski, Richard Nkulikiyinka, Cecilia Freitas, Vanja Vlajnic, Lothar Roessig, Burkert Mathias Pieske · 2022 · ESC Heart Failure
72. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy
    Jishnu Malgie, Pascal R.D. Clephas, Hans‐Peter Brunner‐La Rocca, Rudolf A. de Boer, Jasper Jan Brugts · 2023 · Heart Failure Reviews
73. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health
    Magdalena Madero, Glenn Matthew Chertow, Patrick Barry Mark · 2024 · Kidney Medicine
74. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
    Alberto Ortíz, Charles Joseph Ferro, Olga C. Balafa, Michel Burnier, Robert Ekart, Jean‐Michel Halimi, Reinhold Hugo Kreutz, Patrick Barry Mark, Alexandre Persu, Patrick Rossignol et al. · 2021 · Nephrology Dialysis Transplantation
75. TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity
    Chao‐Yung Wang, Chun‐Chi Chen, Mei-Hsiu Lin, Huiting Su, Ming-Yun Ho, Jih‐Kai Yeh, Ming‐Lung Tsai, Ching‐Lin Hsieh, Ming‐Shien Wen · 2020 · Biology
76. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
    Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa Anne Haendel, Klara Rachel Klein, Hemalkumar B. Mehta, Joshua D. Miller, Richard A. Moffitt et al. · 2021 · Diabetes Care
77. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials
    Ersilia M. DeFilippis, Melvin R. Echols, Philip B. Adamson, Wayne Batchelor, Lauren Beth Cooper, Lawton S. Cooper, Patrice M. Desvigne-Nickens, Richard T. George, Nasrien E. Ibrahim, Mariell L Jessup et al. · 2022 · JAMA Cardiology
78. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer
    Cho‐Han Chiang, Cho-Hung Chiang, Cho‐Hung Chiang, Kevin Sheng‐Kai, Chun-Yu Peng, Yuan Ping Hsia, Chuan‐Sheng Horng, Cheng-Ying Chen, Yu-Cheng Chang, Xin Ya See et al. · 2022 · Heart
79. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials
    Connor P. Oates, Carlos G. Santos‐Gallego, A. Smith, Binaya Basyal, Noah Moss, Iwanari Kawamura, Daniel Ross Musikantow, Mohit K. Turagam, Marc A. Miller, William Whang et al. · 2023 · Journal of Cardiovascular Electrophysiology
80. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
    Lixin Guo, Xinhua Xiao · 2024 · Aging Medicine
81. Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
    Ele Ferrannini, Ashwin C. Murthy, Yong‐ho Lee, Elza Muscelli, Sophie J. Weiss, Rachel M. Ostroff, Naveed A. Sattar, Stephen A. Williams, Peter Ganz · 2020 · Diabetes Care
82. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Jiahua Li, Oltjon Albajrami, Min Zhuo, Chelsea E. Hawley, Julie M. Paik · 2020 · Clinical Journal of the American Society of Nephrology
83. The Treatment of Heart Failure with Reduced Ejection Fraction
    Dominik Berliner, Anja Hänselmann, Johann K Bauersachs · 2020 · Deutsches Ärzteblatt international
84. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium
    William T. Abraham, Mitchell A. Psotka, Mona Fiuzat, Gerasimos S Filippatos, JoAnn M. Lindenfeld, Roxana Mehran, Amrut V. Ambardekar, Peter E. Carson, Richard Jacob, James L. Januzzi et al. · 2020 · European Journal of Heart Failure
85. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
    Samantha T. Harris, Elisabetta Patorno, Min Zhuo, Seoyoung C. Kim, Julie M. Paik · 2021 · Diabetes Care
86. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
    Robert Pietschner, Julie Kolwelter, Agnes Bosch, Kristina Striepe, Susanne Jung, Dennis Kannenkeril, C. Ott, Mario Schiffer, Stephan S. Achenbach, Roland Erich Schmieder · 2021 · Cardiovascular Diabetology
87. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
    Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Peter R Rossing, Luis Miguel Ruilope, John Boletis, Robert Toto, Guillermo E. Umpierrez, Christoph Wanner et al. · 2021 · Nephrology Dialysis Transplantation
88. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
    Julie Kolwelter, Dennis Kannenkeril, Peter R Linz, Susanne Jung, Armin Michael Nagel, Agnes Bosch, Christian Ott, Peter Bramlage, Lisa Nöh, Mario Schiffer et al. · 2022 · Clinical Research in Cardiology
89. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
    Xiaowen Wang, Muthiah Vaduganathan, Brian Lee Claggett, Sheila M. Hegde, Maria A. Pabón, Ian J. Kulac, Orly Vardeny, Eileen O’Meara, Shelley R. Zieroth, Tzvetana Katova et al. · 2022 · Circulation
90. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
    Michael E. Nassif, Sheryl L. Windsor, KENSEY L. GOSCH, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica et al. · 2023 · Circulation Heart Failure
91. All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
    David R. J. Riley, Hani Essa, Philip J. Austin, Frank Preston, Isatu Kargbo, Gema Hernández, Ramandeep Ghuman, Daniel James Cuthbertson, Gregory Y.H. Lip, Uazman Alam · 2023 · Diabetes Obesity and Metabolism
92. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
    Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang · 2024 · The Kaohsiung Journal of Medical Sciences
93. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    Claudio Borghi, Arrigo F.G. Cicero · 2020 · New England Journal of Medicine
94. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
    McMurray, John J.V., Docherty, Kieran F., de Boer, Rudolf A., Hammarstedt, Ann, Kitzman, Dalane W., Kosiborod, Mikhail N., Maria Langkilde, Anna, Reicher, Barry, Senni, Michele, Shah, Sanjiv J. et al. · 2024 · Circulation
95. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
    Malik, Mariam Elmegaard, Falkentoft, Alexander Christian, Jensen, Jesper, Zahir, Deewa, Parveen, Saaima, Alhakak, Amna, Andersson, Charlotte, Petrie, Mark C., Sattar, Naveed, McMurray, John J.V. et al. · 2023 · The Lancet Regional Health - Europe
96. Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure
    Rudolf A. de Boer, Julio E. Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Lynn Keefe · 2020 · British Journal of Clinical Pharmacology
97. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
    Thomas A. Zelniker, David A. Morrow, Ofri Mosenzon, Erica L. Goodrich, Petr Jarolı́m, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding et al. · 2020 · European Journal of Heart Failure
98. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
    Jamie Laura Benham, Jane E. Booth, Ronald Jeremy Sigal, Stella Styliani Daskalopoulou, Alexander A. C. Leung, Doreen M. Rabi · 2021 · IJC Heart & Vasculature
99. Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
    Kai-Jung Lin, Tzu‐Jou Wang, Shang‐Der Chen, Kai-Lieh Lin, Chia‐Wei Liou, Min‐Yu Lan, Yao‐Chung Chuang, Jiin‐Haur Chuang, Pei‐Wen Wang, Jong‐Jer Lee et al. · 2021 · Antioxidants
100. Where the Action Is—Leukocyte Recruitment in Atherosclerosis
     Carina Mauersberger, Julia Hinterdobler, Heribert Schunkert, Thorsten Kessler, Hendrik B. Sager · 2022 · Frontiers in Cardiovascular Medicine